open access

Vol 6, No 1 (2001)
Untitled
Published online: 2001-01-01
Submitted:
Get Citation

74. The rational for optimal combination of radiation therapy and Taxanes in organ preservation treatment of head and neck cancer – project of clinical study

T. Rutkowski, W. Sąsiadek, A. Mucha, K. Składowski
DOI: 10.1016/S1507-1367(01)70444-0
·
Rep Pract Oncol Radiother 2001;6(1):60-61.

open access

Vol 6, No 1 (2001)
Untitled
Published online: 2001-01-01
Submitted:

Abstract

Because Docetaxel has both radiosensitizing properties as well as good anticancer activity by itself in squamous cell carcinomas we are going to attempt concurrent use of Docetaxel and radiochemiotherapy in patients with advanced head and neck cancers (HNC).

Aim

The objective of this study is to evaluate the response rate, loco-regional control, disease – free survival and overall survival in previously untreated inoperable HNC patients.

Methods

This is a project of an open non-randomized, one centre, phase II, one arm study. Total planned dose of RT for GTV is 68 Gy given in 40 fractions, once daily, 7 times per week concomitantly with Cis-Platin, Navelbine and Docetaxel. Eligibility criteria include: proven HNC not treated before, good performance status, normal bone marrow, liver and renal function, age bellow 60. The regimen is proposed as follows: Cis-Platin i.v. 70 mg/m2 on day 1, 22, 43, 64, Navelbine 20 mg/m2 i.v. on day 1, 8, 22, 29, 43, 50, 64 and Docetaxel 30 mg/m2/week or as 1-h infusion of 60 mg/m2 in each 7 days of RT, Ethyol 1000 mg i.v. on day 1, 22, 43 and 250 mg on day 23–42. Radiotherapy 1,7 Gy per fraction continuously on day 23–42 and 44–63. Different treatment schedules of Docetaxel could be used on the basis of cellular activity for a given tumour. So, biopsy should be obtained for analysis of pretreatment levels of apoptosis and oncogenes such as p53, Bax, Bcl-2.

Abstract

Because Docetaxel has both radiosensitizing properties as well as good anticancer activity by itself in squamous cell carcinomas we are going to attempt concurrent use of Docetaxel and radiochemiotherapy in patients with advanced head and neck cancers (HNC).

Aim

The objective of this study is to evaluate the response rate, loco-regional control, disease – free survival and overall survival in previously untreated inoperable HNC patients.

Methods

This is a project of an open non-randomized, one centre, phase II, one arm study. Total planned dose of RT for GTV is 68 Gy given in 40 fractions, once daily, 7 times per week concomitantly with Cis-Platin, Navelbine and Docetaxel. Eligibility criteria include: proven HNC not treated before, good performance status, normal bone marrow, liver and renal function, age bellow 60. The regimen is proposed as follows: Cis-Platin i.v. 70 mg/m2 on day 1, 22, 43, 64, Navelbine 20 mg/m2 i.v. on day 1, 8, 22, 29, 43, 50, 64 and Docetaxel 30 mg/m2/week or as 1-h infusion of 60 mg/m2 in each 7 days of RT, Ethyol 1000 mg i.v. on day 1, 22, 43 and 250 mg on day 23–42. Radiotherapy 1,7 Gy per fraction continuously on day 23–42 and 44–63. Different treatment schedules of Docetaxel could be used on the basis of cellular activity for a given tumour. So, biopsy should be obtained for analysis of pretreatment levels of apoptosis and oncogenes such as p53, Bax, Bcl-2.

Get Citation
About this article
Title

74. The rational for optimal combination of radiation therapy and Taxanes in organ preservation treatment of head and neck cancer – project of clinical study

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 6, No 1 (2001)

Pages

60-61

Published online

2001-01-01

DOI

10.1016/S1507-1367(01)70444-0

Bibliographic record

Rep Pract Oncol Radiother 2001;6(1):60-61.

Authors

T. Rutkowski
W. Sąsiadek
A. Mucha
K. Składowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl